New eye drop shows promise for rare corneal disease
NCT ID NCT06597422
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an experimental eye drop called STSP-0902 in 82 healthy volunteers to see if it is safe and how the body processes it. The study involved single and multiple doses, with some participants getting a placebo. The goal is to eventually treat neurotrophic keratitis, a rare condition where the cornea loses feeling and can get damaged.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
STSP-0902 ophthalmic solution (eye drops)
What this could lead to
If successful, this could lead to a treatment for neurotrophic keratitis, a rare eye condition that can cause vision loss.
What could go wrong
This is an early Phase 1 trial in healthy people, not patients, so it only tests safety and dosing. It may not work in actual disease or may have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROTROPHIC KERATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, 100005, China